Stock Scorecard
Stock Summary for Vor Biopharma Inc (VOR) - $14.53 as of 12/26/2025 8:38:28 AM EST
Total Score
11 out of 30
Safety Score
16 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for VOR
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for VOR
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for VOR
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for VOR
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for VOR (16 out of 100)
| Stock Price Rating (Max of 10) | 5 |
| Historical Stock Price Rating (Max of 10) | 10 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 6 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for VOR
Financial Details for VOR
Company Overview |
|
|---|---|
| Ticker | VOR |
| Company Name | Vor Biopharma Inc |
| Country | N/A |
| Description | Vor Biopharma Inc. is a forward-thinking biopharmaceutical company located in Cambridge, Massachusetts, focused on transforming cancer treatment through its innovative engineered hematopoietic stem cell (eHSC) therapies. Utilizing cutting-edge proprietary technology platforms, Vor is dedicated to delivering targeted therapies that not only enhance patient outcomes but also aim for durable responses and improved survival rates. With a strong emphasis on advancing cell therapies and a strategic position within the dynamic oncology landscape, Vor presents attractive investment prospects for institutional investors eager to support pioneering advancements in cancer therapeutics. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 14.53 |
| Price 4 Years Ago | 232.40 |
| Last Day Price Updated | 12/26/2025 8:38:28 AM EST |
| Last Day Volume | 625,314 |
| Average Daily Volume | 2,606,060 |
| 52-Week High | 65.80 |
| 52-Week Low | 2.62 |
| Last Price to 52 Week Low | 454.58% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 72.45 |
| Sector PE | 128.95 |
| 5-Year Average PE | -40.74 |
| Free Cash Flow Ratio | 1.98 |
| Industry Free Cash Flow Ratio | 14.50 |
| Sector Free Cash Flow Ratio | 31.21 |
| Current Ratio Most Recent Quarter | 9.16 |
| Total Cash Per Share | 7.32 |
| Book Value Per Share Most Recent Quarter | -246.54 |
| Price to Book Ratio | 3.14 |
| Industry Price to Book Ratio | 11.14 |
| Sector Price to Book Ratio | 43.34 |
| Price to Sales Ratio Twelve Trailing Months | 0.00 |
| Industry Price to Sales Ratio Twelve Trailing Months | 38.48 |
| Sector Price to Sales Ratio Twelve Trailing Months | 21.21 |
| Analyst Buy Ratings | 3 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 21,910,600 |
| Market Capitalization | 318,361,018 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 0.81% |
| Reported EPS 12 Trailing Months | -386.86 |
| Reported EPS Past Year | -373.10 |
| Reported EPS Prior Year | -1.70 |
| Net Income Twelve Trailing Months | -2,449,551,000 |
| Net Income Past Year | -116,914,000 |
| Net Income Prior Year | -117,863,000 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 160,462,000 |
| Total Cash Past Year | 81,949,000 |
| Total Cash Prior Year | 31,360,000 |
| Net Cash Position Most Recent Quarter | 160,462,000 |
| Net Cash Position Past Year | 81,949,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 0.00 |
| Total Stockholder Equity Past Year | 96,664,000 |
| Total Stockholder Equity Prior Year | 150,724,000 |
| Total Stockholder Equity Most Recent Quarter | -2,225,487,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -144,674,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -6.60 |
| Free Cash Flow Past Year | -99,889,000 |
| Free Cash Flow Prior Year | -101,361,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.25 |
| MACD Signal | -1.10 |
| 20-Day Bollinger Lower Band | 0.53 |
| 20-Day Bollinger Middle Band | 25.08 |
| 20-Day Bollinger Upper Band | 49.63 |
| Beta | 2.08 |
| RSI | 52.17 |
| 50-Day SMA | 23.23 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 12/27/2025 10:26:28 AM EST |